Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response
Abstract The rapid spread of COVID-19 underscores the need for new treatments. Here we report that cannabidiol (CBD),…
-
-
The potential of cannabidiol in the COVID-19 pandemic
Identifying candidate drugs effective in the new coronavirus disease 2019 (Covid‐19) is crucial, pending a vaccine against SARS‐CoV2….
-
Fighting the storm: novel anti- TNFα and anti-IL-6 C. sativa lines to tame cytokine storm in COVID-19
Overall, we are the first to show that application of C. sativa extracts profoundly decreases the level of…
-
Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?
In murine models of lung injury, CBD reduced lipopolysaccharide (LPS)-induced acute pulmonary inflammation [41,42]. In rat models of…
-
SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?
Like Δ9-tetrahydrocannabinol (Δ9-THC), the most well-studied cannabinoid, CBD decreased lung inflammation in a murine model of acute lung…
-
In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues
The observed down-regulation of ACE2 gene expression by several tested extracts of C. sativa is a novel and…